BioSpace News Archive

Coya Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, announced that it will host a key opinion leader webinar on ALS001, the Company’s lead asset for the treatment of amyotrophic lateral sclerosis, on Friday, June 11, 2021 at 11:30 a.m. ET.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that that Health Care Service Corporation has issued a positive coverage policy, effective June 15, 2021, applicable to the BrainsWay Deep TMS™ system for the treatment of obsessive-compulsive disorder.

Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that it will host a key opinion leader webinar on the myelofibrosis treatment landscape and the current and potential future treatments on Wednesday, June 9, 2021 at 8am Eastern Time.

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced that it has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin, a sodium-glucose cotransport-2 inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis.

Cidara Therapeutics, Inc. announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidara’s novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2021 Conference, which takes place online from June 11-12, 2021.

BetterLife Pharma Inc., an emerging biotech company, is pleased to announce that it has appointed Mr. Henri Sant-Cassia, co-founder of The Conscious Fund, to its Board of Directors.

Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced positive data from an interim analysis of an investigator-initiated study of alvelestat in patients with Bronchiolitis Obliterans Syndrome following hematopoietic stem cell transplantation.

Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response

Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced that it will present at two upcoming virtual investor conferences

Genmab A/S and Bolt Biotherapeutics, Inc. announced that the companies have entered into an oncology research and development collaboration.